Rescue Therapy With Pegcetacoplan in a Patient With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Kidney International Reports 2026 Open access

Read full text
Authors: Hormaz Dastoor, Emad Khater, Suhail Al Salam, Stephen Geoffrey Holt
DOI: 10.1016/j.ekir.2026.103770
Cited by: 0
References: 3

Abstract

In the pivotal phase 2 and phase 3 VALIANT trials, pegcetacoplan reduced proteinuria and stabilised kidney function in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.1,2 However, the trials enrolled patients with an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2,2 leaving limited evidence in this population. We report the successful use of pegcetacoplan in a patient with severe biopsy-proven proliferative glomerulonephritis with monoclonal immunoglobulin deposits and low eGFR with impending dialysis.

Fields of Study & Subjects

Platelet Disorders and Treatments Renal Diseases and Glomerulopathies Complement system in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
3
Pages
103770–103770
Publication date
8 January 2026
Language
EN